EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Erectile Dysfunction - Pipeline Review, H1 2017

  • ID: 4091118
  • Report
  • February 2017
  • 103 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Apricus Biosciences Inc
  • Biolab Farmaceutica Ltda
  • Can-Fite BioPharma Ltd
  • Humanetics Corp
  • iX Biopharma Ltd
  • Monosol Rx LLC
  • MORE
Erectile Dysfunction - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 4, 2, 2, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apricus Biosciences Inc
  • Biolab Farmaceutica Ltda
  • Can-Fite BioPharma Ltd
  • Humanetics Corp
  • iX Biopharma Ltd
  • Monosol Rx LLC
  • MORE
Introduction

Erectile Dysfunction - Overview

Erectile Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Erectile Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Erectile Dysfunction - Companies Involved in Therapeutics Development

Apricus Biosciences Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Biopharm GmbH

Can-Fite BioPharma Ltd

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Hanmi Pharmaceuticals Co Ltd

Humanetics Corp

IntelGenx Corp

Ion Channel Innovations LLC

iX Biopharma Ltd

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Monosol Rx LLC

NAL Pharmaceuticals Ltd

Palatin Technologies Inc

Pharmicell Co Ltd

Suda Ltd

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Erectile Dysfunction - Drug Profiles

(tadalafil + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-ED - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKK-01PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCP-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPED-2015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-6932 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-0092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPN-729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLFIA-330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YBH-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Erectile Dysfunction - Dormant Projects

Erectile Dysfunction - Discontinued Products

Erectile Dysfunction - Product Development Milestones

Featured News & Press Releases

Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm

Jan 24, 2017: Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil

Nov 28, 2016: MonoSol Rx Submits New Drug Application for Tadalafil PharmFilm

Nov 09, 2016: Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug

Sep 13, 2016: iX Biopharma Announces Positive Results from Pivotal Study of Erectile Dysfunction Drug

Jul 27, 2016: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents

May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting

Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose

Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil

Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix

Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

Jan 27, 2015: Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies

Dec 09, 2014: Can-Fite to Initiate the Development Program of its Next Generation Drug CF602

Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Erectile Dysfunction, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1

Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1

Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1

Erectile Dysfunction - Pipeline by Biopharm GmbH, H1

Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1

Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1

Erectile Dysfunction - Pipeline by Futura Medical Plc, H1

Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1

Erectile Dysfunction - Pipeline by Humanetics Corp, H1

Erectile Dysfunction - Pipeline by IntelGenx Corp, H1

Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1

Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1

Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1

Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1

Erectile Dysfunction - Pipeline by Monosol Rx LLC, H1

Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1

Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1

Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1

Erectile Dysfunction - Pipeline by Suda Ltd, H1

Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1

Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1

Erectile Dysfunction - Dormant Projects, H1

Erectile Dysfunction - Dormant Projects, H1 2017 (Contd..1), H1

Erectile Dysfunction - Discontinued Products, H1

List of Figures:

Number of Products under Development for Erectile Dysfunction, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Apricus Biosciences Inc
  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Futura Medical Plc
  • Hanmi Pharmaceuticals Co Ltd
  • Humanetics Corp
  • IntelGenx Corp
  • Ion Channel Innovations LLC
  • iX Biopharma Ltd
  • Mezzion Pharma Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Monosol Rx LLC
  • NAL Pharmaceuticals Ltd
  • Palatin Technologies Inc
  • Pharmicell Co Ltd
  • Suda Ltd
  • XuanZhu Pharma Co Ltd
  • Yungjin Pharm Co Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll